Mild cognitive impairment and new medications for Alzheimer’s disease

Will monoclonal antibodies for Alzheimer’s Disease change disease outcomes? There is now evidence that the use of monoclonal antibody therapy in early disease reduces amyloid load - but does it improve cognition?

In response to the growing need for GPs to be adept in recognising and managing mild cognitive impairment, we have partnered with Dementia Training Australia to bring you this webinar focusing on the diagnosis of mild cognitive impairment and evaluation of patient eligibility for emerging therapies.

This webinar will feature a case study to demonstrate how to identify mild cognitive impairment including discussing the implications and treatment options with the patient. Blood biomarkers are showing promise in enhancing the accuracy of early Alzheimer’s Disease diagnosis and may play a role in guiding treatment decisions. Their role in a general practice setting will be discussed.

Learning outcomes

• Describe the key features of Mild Cognitive Impairment
• Outline the pathway to new monoclonal antibodies
• Discuss how blood biomarkers may be used in improving diagnostic accuracy of Alzheimer's Disease

Webinar Partner 

Medcast is proud to be partnering with Dementia Training Australia to bring you this important webinar series.